Subscribe
shutterstock_1392543575_pavel_kapysh
Pavel Kapysh / Shutterstock.com
3 January 2020AmericasSarah Morgan

Adamas settles Gocovri clash with Sandoz

California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
AbbVie secures another Humira settlement
12 October 2018   AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.
Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
AbbVie secures another Humira settlement
12 October 2018   AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.
Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

More on this story

Americas
AbbVie secures another Humira settlement
12 October 2018   AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.
Big Pharma
Amphastar enters into $59m settlement with Sandoz and Momenta
20 June 2019   US pharmaceutical company Amphastar Pharmaceuticals is to receive $59.9 million in a settlement agreement with two of its competitors, Sandoz and Momenta Pharmaceuticals.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers